Evaluation of the efficacy and safety of human coagulation factor Ⅷ in the treatment of hemophilia A patients
Journal Title: Chinese Journal of Blood Transfusion - Year 2022, Vol 35, Issue 12
Abstract
Objective To evaluate the efficacy and safety of human coagulation factor Ⅷ developed by Shenzhen Weiguang Biological products Co, Ltd in the treatment of patients with hemophilia A. Methods A prospective, multi-center, open, single-group clinical study was conducted. A total of 65 subjects with hemophilia A were enrolled, and human coagulation factor Ⅷ(FⅧ) was injected according to the patients’ bleeding severity. The improvement score of bleeding symptoms and signs after the first infusion of the first bleeding event and the transfusion efficiency of FⅧ activity at 10 min and 1 hour after infusion were taken as the main efficacy indexes. The improvement scores of bleeding symptoms and signs after the first infusion and the increase of FⅧ activity at 10 min and 1 hour after infusion were the secondary efficacy indexes. Results The 65 subjects were enrolled in safety analysis set (SS) and full analysis set (FAS), and 58 of them were enrolled in protocol analysis set (PPS). Ten minutes and one hour after the first infusion, the level of factor Ⅷ activity in the subjects increased significantly, and the FⅧ activity increased by 100% or more in more than 79% of the subjects. The average infusion efficiency of FⅧ activity in all subjects was more than 100%. In 70% of the subjects, the pain was relieved rapidly and /or the bleeding symptoms were significantly improved 8 hours after each bleeding infusion, and the improvement rate of bleeding symptoms and signs reached 100% 72 hours after infusion. Conclusion After infusion of human coagulation factor Ⅷ, the activity level of factor Ⅷ in patients with hemophilia A significantly increased. The infusion efficiency can reach a optimal level, and the bleeding symptoms can be significantly improved.
Authors and Affiliations
Ruyi CHEN, Yan WU, Yiyun LIU, Mingxia HOU, Qingshuang SONG, Xuanlin ZHONG, Xueyun WANG, Wenjie XIE, Caiping GUO, Zhan ZHANG, Yunjia ZHANG
Keywords
Related Articles
- EP ID EP738431
- DOI 10.13303/j.cjbt.issn.1004-549x.2022.12.008
- Views 53
- Downloads 0
Research progress on platelet rich plasma in management of patients with knee osteoarthritis
Knee osteoarthritis (KOA) is a common chronic degenerative disease of cartilage, which often occurs in middle-aged and elderly patients. It can cause joint swelling, pain and limited movement. With the aging population g...
Effects of acute normovolemic hemodilution combined with intraoperative recycled autotransfusion on blood transfusion volume and coagulation function in elderly patients undergoing cardiac surgery
Objective To explore the effects of acute normovolemic hemodilution (ANH) combined with intraoperative recycled autotransfusion on blood transfusion volume and coagulation function in elderly patients undergoing cardiac...
Analysis of perioperative blood transfusion and the influencing factors of mass-transfusion in patients underwent heart transplantation
Objective To provide references for clinical prediction of blood preparation and blood consumption, as well as the influencing factors of mass-transfusion by analyzing the perioperative blood transfusion in patients unde...
Perioperative transfusion strategies for patients with rare coagulation factor deficiency
Objective To discuss the perioperative blood transfusion strategy of patients with hereditary coagulation factor deficiency through the perioperative blood coagulation management of a patient with coagulation factor Ⅺ de...
Clinical manifestations and genetic mutation analysis of 20 patients with congenital Fibrinogen disorders
Objective To retrospectively analyze the clinical manifestations, related laboratory examinations and gene mutation of 20 patients with congenital Fibrinogen disorders (CFD) admitted to our hospital from February 2017 to...